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Abstract
 
Interleukin (IL)-2 interacts with two types of functional receptors (IL-2R
 
abg
 
 and IL-2R
 
bg
 
) and
acts on a broad range of target cells involved in inflammatory reactions and immune responses.
For the first time, we show that a chemically synthesized fragment of the IL-2 sequence can fold
into a molecule mimicking the quaternary structure of a hemopoietin. Indeed, peptide p1–30
(containing amino acids 1–30, covering the entire 
 
a
 
 helix A of IL-2) spontaneously folds into an
 
a
 
-helical homotetramer and stimulates the growth of T cell lines expressing human IL-2R
 
b
 
,
whereas shorter versions of the peptide lack helical structure and are inactive. We also demon-
strate that this neocytokine interacts with a previously undescribed dimeric form of IL-2R
 
b
 
. In
agreement with its binding to IL-2R
 
b
 
, p1–30 activates Shc and p56
 
lck
 
 but unlike IL-2, fails to ac-
tivate Janus kinase (Jak)1, Jak3, and signal transducer and activator of transcription 5 (STAT5).
Unexpectedly, we also show that p1–30 activates Tyk2, thus suggesting that IL-2R
 
b
 
 may bind to
different Jaks depending on its oligomerization. At the cellular level, p1–30 induces lymphokine-
activated killer (LAK) cells and preferentially activates CD8
 
low
 
 lymphocytes and natural killer cells,
which constitutively express IL-2R
 
b
 
. A significant interferon 
 
g
 
 production is also detected after
 
p1–30 stimulation. A mutant form of p1–30 (Asp20
 
®
 
Lys), which is likely unable to induce vas-
cular leak syndrome, remains capable of generating LAK cells, like the original p1–30 peptide. Al-
together, our data suggest that p1–30 has therapeutic potential.
Key words: interleukin 2 mimetic • synthetic hemopoietin • dimeric interleukin 2 receptor
 
b 
 
chain
 
 
 
• signal transduction • natural killer cells
 
Introduction
 
Human IL-2 is a 133–amino acid (aa)
 
1
 
 polypeptide with a
molecular mass of 15–18 kD depending on the degree of
glycosylation (1, 2). Its structure is made up of a compact
core bundle of four anti-parallel 
 
a
 
 helices connected by
three loops (3). IL-2 is a major cytokine regulating the im-
mune system, with its primary biological activity consisting
in promoting clonal expansion of antigen-activated T lym-
phocytes. Furthermore, IL-2 induces lymphokine-activated
killer (LAK) and NK cell cytotoxicity against tumor cells or
virus-infected cells (4).
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Abbreviations used in this paper:
 
 A domain, acidic domain; aa, amino acid;
CD, circular dichroism; EMSA, electrophoretic mobility shift assay; EPO,
erythropoietin; FLC, fluorescein; GAS, IFN-
 
g
 
–activated sequence; Jak, Ja-
nus kinase; 
 
K
 
d
 
, dissociation constant; LAK, lymphokine-activated killer cell;
PTK, protein tyrosine kinase; S domain, serine-rich domain; STAT, signal
transducer and activator of transcription; VLS, vascular leak syndrome. 
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IL-2 Partial Mimetic, Inducing LAK Cells
 
The effects of IL-2 on its target cells are mediated through
specific cell surface receptors made up of three chains (IL-
2R
 
a
 
, IL-2R
 
b
 
, and IL-2R
 
g
 
 [5]). IL-2R
 
a
 
 is a 55-kD protein
that binds to IL-2 with a dissociation constant (
 
K
 
d
 
) value of
 
z
 
10 nM (6, 7). The second IL-2R component, IL-2R
 
b
 
, is a
75-kD protein with a large (286 aa) intracytoplasmic domain
(8, 9). The last component to be identified, IL-2R
 
g
 
, is a
64-kD protein (10, 11). IL-2R
 
b
 
 and IL-2R
 
g
 
 belong to the
hemopoietin receptor family (12), whereas IL-2R
 
a
 
 along
with IL-15R
 
a
 
 belong to a distinct family of molecules
(13). In the human system, two receptor complexes are
functional: the association of human IL-2R
 
b
 
 and IL-2R
 
g
 
forms an intermediate affinity receptor with a 
 
K
 
d
 
 value of
 
z
 
1 nM, whereas expression of all three chains leads to the
formation of a high affinity IL-2R (
 
K
 
d
 
 
 
z 
 
10 pM). A struc-
tural model for the IL-2/IL-2R complex derived from
the three-dimensional structure of the growth hormone–
growth hormone receptor cocrystals has been proposed by
Bamborough et al. (14) and is supported by experimental
data (15–18).
Heterodimerization of IL-2R
 
b
 
 and IL-2R
 
g
 
 subunits
triggers downstream signals that involve the tyrosine phos-
phorylation of a large array of cellular proteins. IL-2R
 
b
 
plays a critical role in this signal transduction cascade. After
IL-2 stimulation, IL-2R
 
b
 
 recruits protein tyrosine kinases
(PTKs: p56
 
lck
 
, Syk, and Janus kinases [Jaks]) and an adapter
protein (Shc), all of which play an essential role in lympho-
cyte activation. After interaction with phosphorylated Tyr338
of IL-2R
 
b
 
, Shc invokes the RAS and phosphatidylinositol
3-kinase signaling pathways that are essential in the control
of cellular activation and proliferation. These pathways are
dependent on two subregions of the IL-2R
 
b
 
 chain, the
serine-rich (S) and the acidic (A) domains. p56
 
lck
 
 protein is
associated with the A domain of IL-2R
 
b
 
 and may be in-
volved in the phosphorylation of Shc and consequently in
the regulation of RAS (19). The Jak–signal transducer and
activator of transcription (STAT) pathway is also impli-
cated in the course of IL-2 activation and involves both the
IL-2R
 
b
 
 and IL-2R
 
g
 
 subunits, which are constitutively as-
sociated with Jak1 and Jak3, respectively. As a consequence
of Jak1/Jak3 phosphorylation, STAT5 is activated after
binding to phosphorylated Tyr510 of IL-2R
 
b
 
. IL-2 in-
duces the phosphorylation, dimerization, and nuclear trans-
location of STAT5 (20).
In previous studies, we have demonstrated that the 
 
a
 
 he-
lix A of IL-2 (aa 6–30) is essential for binding to the IL-
2R
 
b
 
 chain (21). Here, we report on the characterization of
peptide p1–30 (comprising aa 1–30 of human IL-2), which
encompasses the entire 
 
a
 
 helix A of IL-2 (see Table I, top).
The biological properties of this peptide, its preliminary
structural features, and the signaling events it induces indi-
cate that we have isolated a partial IL-2 mimetic, which acts
specifically on IL-2R
 
b
 
 dimers. At the immunological level,
p1–30 is able to generate LAK cells and specifically acti-
vates NK and CD8 T cells, which express large amounts of
IL-2R
 
b
 
 and participate in cytotoxic responses. Moreover,
p1–30 induces the production of IFN-
 
g
 
, also known for its
direct and indirect activity against tumor cells. For the first
 
time, we demonstrate that a chemically synthesized cyto-
kine fragment is able to fold into a neocytokine structure.
This new molecule exhibits many of the properties of
members of the hemopoietin family and has therapeutic
potential.
 
Materials and Methods
 
Cell Lines and Proliferation Assays.
 
TS1 is a murine T cell line
expressing mouse IL-2R
 
g
 
 chain only and grows in IL-4 or IL-9.
TS1
 
b
 
 cells are TS1 cells transfected with human IL-2R
 
b
 
 and are
in addition able to grow in IL-2. The murine cell line 8.2 ex-
presses mouse IL-2R
 
b
 
 and mouse IL-2R
 
g
 
 and grows in IL-4
only (22). Kit 225 is an IL-2–dependent human CD4 T cell line,
originally derived from a human adult T cell lymphoma (23).
For proliferation assays, cells were stimulated in 96-well flat-
bottomed microtiter plates at various concentrations of cytokines,
IL-2 peptides, or both, and after 36 h of stimulation, [
 
3
 
H]TdR
incorporation was measured. For testing p1–30 activity, cells were
stimulated with either peptide alone or in combination with IL-2
or IL-4. Certain p1–30 effects were more readily detectable when
peptide was used in combination with cytokines. The inhibitory
effect of neutralizing anti–human IL-2R
 
b
 
 mAb A41 and neutral-
izing anti–mouse IL-2R
 
g
 
 mAb 3E12 plus 4G3 was tested on
proliferation induced by cytokines or peptide p1–30 alone.
 
Peptides, Cytokines, and Soluble IL-2R
 
b
 
 31–230.
 
Peptides were
synthesized by the step-wise solid-phase reaction using the boc/
trifluoroacetic acid method (24), on a 
 
p
 
-methylbenzhydrylamine
resin with an Applied Biosystems 430A peptide synthesizer, as de-
scribed previously (21). After purification, peptides were verified
by mass spectrometry and amino acid analysis after total hydro-
lysis. The following IL-2 peptides were used in this study: p1–30,
p1–22, p10–30, p1–10, p5–15, p10–20, p15–25, p20–30, p1–31,
p1–31(Lys20), and p1–30Cys.
p1–30Cys was labeled on the terminal Cys31 with a fluorescein
group (FLC) and purified by two successive rounds of exclusion
chromatography on a G25 resin column (Amersham Pharmacia
Biotech). Fractions with greater absorbance ratios at 242 and 490
nm were selected. The purified labeled peptide p1–30Cys-FLC
(mol. wt. 3805, 
 
e
 
242nm
 
 2,104 M
 
2
 
1
 
cm
 
2
 
1
 
, 
 
e
 
490nm
 
 83,000 M
 
2
 
1
 
cm
 
2
 
1
 
,
 
n
 
 
 
5
 
 
 
0.732 ml/mg) consisted of 
 
.
 
92% of the total peptide amount.
The cytokines used in this work were human rIL-2 (Chiron),
mouse rIL-4 (obtained from Dr. T. Honjo, University of Kyoto, Ky-
oto, Japan) or purified murine IL-9 (provided by Dr. J. Van Snick,
Institut Ludwig pour la Recherche sur le Cancer, Brussels, Belgium).
The 31–230 aa residues of the IL-2R
 
b
 
 chain (IL-2 R
 
b 31–230;
mol. wt. 23,352) were produced from a transfected Chinese
hamster ovary (CHO) cell line and immunopurified according to
established techniques (25). The molar extinction coefficient was
calculated from the UV absorption spectrum at 280 nm (59,450
M21cm21) and amino acid analysis.
After stimulation with IL-2, p1–30, or both, IFN-g produc-
tion was measured on PBMC supernatants with a commercial
enzyme immunoassay (Immunotech).
Circular Dichroism. Molar extinction coefficients were calcu-
lated from the UV absorption spectrum and amino acid analysis
(p1–30: 12,133 and 2,047 M21cm21 at 230 and 242 nm, respec-
tively). Circular dichroism (CD) measurements were recorded on
a spectropolarimeter (model CD6; Jobin Yvon) from 5–20 scans in
far UV from 180 to 260 nm at 208C in 20 mM sodium phosphate
buffer (pH 7.2). The percentage of helix content was estimated
from CD spectra according to an established procedure (26).531 Eckenberg et al.
Molecular Weight Analysis. Size exclusion chromatography analy-
sis was performed with a fast protein liquid chromatography (FPLC)
system. p1–30 solutions (100 ml at 150 mM in sodium phosphate 20
mM, pH 7.2) were injected on a Superdex S200 HR 10–30 column
(24 ml; Amersham Pharmacia Biotech) equilibrated with the same
buffer at room temperature at a constant flow rate (0.5 ml/min) and
calibrated with molecular weight markers. Concentration profiles
were recorded at 230 nm for peptides and 254 nm for proteins.
Diffusion–sedimentation equilibrium studies were performed at
208C with peptide solutions (10 and 150 mM) or IL-2Rb 31–200
(1 and 14 mM) in 20 mM sodium phosphate (pH 7.2), with a
Beckman XL-A analytical ultracentrifuge at 25 and 42 krpm us-
ing standard double sector cells with 1.2-mm-thick aluminum
centerpieces. Absorbances were recorded at 230, 242, and 360 nm
for peptides and 280 nm for IL-2Rb 31–200 as a function of ra-
dial distance. After at least 18 h, we verified that equilibrium was
reached and recorded 10–99 successive scans. Base lines were re-
corded at 360 nm and 42 krpm. Protein concentration profiles at
equilibrium were fitted to different models with the Origin-based
Optima™ XL-A data analysis software from Beckman (single
ideal component, two ideal components, and association of iden-
tical ideal components). Best fits were retained on the basis of
both the x2 value and the lack of systematic deviation of the re-
siduals. In all cases, the base line was fixed at zero absorbance and
not allowed to float during the fitting procedure. The value of
the partial specific volume (n), used for molecular weight calcula-
tions, was calulated from the amino acid composition of peptides
(p1–10 [in ml/mg], n 5 0.710; p5–15, 0.722; p10–20, 0.759;
p1–22, 0.720; p10–30, 0.752; p1–30, 0.710; p1–30Cys, 0.710;
and p1–30Cys-FLC, 0.732) and IL-2Rb 31–200 (0.719 ml/mg).
The solvent density was taken as 1.001 g/ml.
Binding of p1–30, p1–30Cys, and p1–30Cys-FLC on IL-2Rb
31–200 was tested by analytical ultracentrifugation in 20 mM so-
dium phosphate, pH 7.2, at 208C. For each experiment, one cell
was filled with peptide, one with IL-2Rb 31–200, and the last
with the mixture of peptide and IL-2Rb 31–200 in the three-cell
rotor. Peptides and IL-2Rb 31–200 concentrations were 150 and
14 mM, respectively. Absorbance was recorded at a wavelength
of 242, 280, and 490 nm after reaching equilibrium at 22, 25, 28,
and 42 krpm.
Immunoprecipitation and Western Blot Analysis. Kit 225 cells were
starved for 48 h in IL-2–free medium and then stimulated at
378C with the following ligands: IL-2 (10 nM), p1–30 (60 mM),
or IFN-a (1,000 U/ml). 5 3 106 cells were lysed in 125 ml of ly-
sis buffer (50 mM Tris, pH 8, 10% glycerol, 200 mM NaCl, 0.5%
NP-40, and 0.1 mM EDTA), supplemented with each of the
protease inhibitors leupeptin, aprotinin, and PMSF at 10 mg/ml,
and with the phosphatase inhibitors sodium fluoride (50 mM)
and sodium orthovanadate (1 mM). For immunoprecipitation,
lysates of 10 3 106 cells were immunoprecipitated with the indi-
cated mAbs for 1 h at 48C. After electrophoresis on an 8% SDS-
polyacrylamide gel, the proteins were transferred to Immobilon
membranes (Millipore Corp.). The immunoblots were incubated
with antiphosphotyrosine mouse mAb 4G10 (Upstate Biotech-
nology), mAb to human Shc (Transduction Laboratories), or
mAb to human Jak1, Jak2 (Upstate Biotechnology), Jak3 (Santa
Cruz Biotechnology), or Tyk2. After incubation with an anti–
mouse Ig peroxidase-conjugated mAb (Amersham Pharmacia
Biotech) or an anti–rabbit Ig peroxidase-conjugated mAb (Bio-
sys), reactive protein bands were visualized by enhanced chemilu-
minescence (ECL; Amersham Pharmacia Biotech).
For the in vitro kinase assay, p56lck was immunoprecipitated
from Kit 225 lysates with an anti–human p56lck mAb. Immuno-
precipitates thus obtained were suspended for 5 min at 258C in
kinase buffer, pH 7 (200 mM Mops, 50 mM Na-O-Ac, 10 mM
EDTA, 10 mM MgCl2), containing 38 mg of enolase (Sigma-
Aldrich), [g-32P]ATP, and unlabeled ATP (10 mM). The samples
were then electrophoresed on an 8% (SDS-PAGE) gel before
drying and exposure to film.
Induction of LAK Cells. PBMCs were stimulated for 3 or 6 d
in complete medium (RPMI 1640 supplemented with 10% nor-
mal human serum) in the presence of p1–30, p1–31(Lys20), or
IL-2. K562 or Daudi target cells (5 3 103 in 0.1 ml) labeled with
Na2
51CrO4 (Amersham Pharmacia Biotech) were mixed into
round-bottomed microwells with an equal volume of effector
cells at various E/T ratios. After 4 h of incubation at 378C, the
plates were centrifuged at 2,000 g for 2 min, and cell-free super-
natants were collected using a LumaPlate 96 cell harvester (Lumac-
LSC). Supernatant radioactivity was assayed using an automated
MicroBeta 1450 TriLux g-counter (Wallac). Spontaneous release
was determined by incubating target cells in medium alone.
Maximum release was determined by adding 0.1 ml of 1 M HCl
to the target cell suspension. The percentage of specific lysis was cal-
culated as follows: 100 3 (experimental 51Cr release 2 spontaneous
51Cr release)/(maximum 51Cr release 2 spontaneous 51Cr release).
FACS® Analysis. Lymphocyte subsets were detected by direct
labeling using the following mAbs labeled with R-PE: anti-CD4
(MT310; Dako), anti-CD8 (DK25; Dako), anti-CD20 (B-Ly1;
Dako), and anti-CD56 (Moc-1; Dako). Anti-CD69 (Klon FN50;
Dako) labeled with FITC was used as an early activation marker
for the different lymphocyte subsets. Tricolor mouse anti–human
CD14 (MHCD1406; Caltag Laboratories) was used to exclude
monocytes from the analysis.
After 0, 24, 48, or 72 h of activation in the presence of the
indicated concentration of IL-2 and/or p1–30, cells (2 3 105 in
200 ml) were simultaneously labeled with anti-subset– and anti-
CD69–specific mAbs. After the staining procedure, cells were
washed and fixed in 1% paraformaldehyde. A total of 2 3 104
cells per sample were analyzed with a FACScan™ flow cytome-
ter using CELLQuest™ 1.2 software (Becton Dickinson).
Results
Biological Activity of IL-2 Peptide p1–30 and the Role of Hu-
man IL-2Rb in p1–30 Activity. The biological activity of
peptide p1–30 was assayed on the proliferation of a mouse
T cell line, which was engineered to express the human
IL-2Rb (TS1b). p1–30 induced a proliferative response in
TS1b (maximal proliferation at 60 mM; Fig. 1 A). When
tested in the presence of 1 or 10 nM of IL-2, a synergistic
effect was observed for all tested concentrations of p1–30
compared with either p1–30 or IL-2 alone (Fig. 1 B). At
60 mM p1–30 and either 1 or 10 nM IL-2, the proliferative
response was twofold higher than the sum of each individ-
ual response. Remarkably, although 10 nM of IL-2 alone
induced optimal TS1b cell proliferation, addition of p1–30
led to a large increase in the proliferative response. Synergy
was also observed with IL-4 (Fig. 1 E). The effect of shorter
peptides in the helix A region was also evaluated on prolif-
eration and compared with that of p1–30 (Table I).
The critical role of human IL-2Rb in the p1–30 effect
was studied using neutralizing anti–human IL-2Rb mAb
A41 (Fig. 1 C). As expected, mAb A41 inhibited the IL-2–532 IL-2 Partial Mimetic, Inducing LAK Cells
induced TS1b proliferation. This antibody also inhibited
the p1–30-induced proliferation with a comparable efficiency,
but had no effect on IL-9–induced proliferation (Fig. 1 C).
In contrast, as shown in Fig. 1 D, IL-2Rg plays a minor
role if any in p1–30 activity, as measured on TS1b cells.
Further analysis of the role of IL-2Rb on the synergistic
effect induced by p1–30 was undertaken using various cell
lines expressing different combinations of IL-2R chains. TS1
expresses murine IL-2Rg, TS1b expresses human IL-2Rb
and murine IL-2Rg, and 8.2 expresses murine IL-2Rb and
murine IL-2Rg (Fig. 1 E). Synergy between IL-4 and
p1–30 was observed only in TS1b cells, thus demonstrating
that the introduction of a human IL-2Rb is sufficient to
confer responsiveness to p1–30. Results obtained with 8.2
cells are in agreement with the observation that human IL-2
does not bind murine IL-2Rb (22).
Structure–Function Analysis of p1–30. The secondary struc-
ture of various peptide segments in the region of aa residues
1–30 was studied by CD. Fig. 2 A shows the spectra ob-
tained in the far UV range with a peptide concentration of
150 mM. Only two peptides showed .5% helical confor-
mation: p10–30 (35 6 5%) and p1–30 (50 6 5%). The
concentration dependence of the dichroic signal was evalu-
ated between 3 and 150 mM for p1–30 (Fig. 2 A, insert)
and p10–30 (data not shown). The helix content was de-
pendent on the peptide concentration, and a maximum he-
lix content was obtained at 30 mM of p1–30 and at 100 mM
of p10–30.
The quaternary structure of p1–30 was first analyzed by
Figure 1. p1–30 induces cell proliferation and acts in synergy with IL-2.
Role of human IL-2b. TS1b cells were stimulated with p1–30 (up to
100 mM) in the absence (A) or presence (B) of 1 or 10 nM IL-2. This was
followed by measuring [3H]TdR incorporation. Proliferative responses
induced with 1 or 10 nM of IL-2 were 38,148 and 72,370 cpm, respec-
tively. Optimal responses were obtained with 60 mM of p1–30. Back-
ground was subtracted. (C) Effects of neutralizing anti–human IL-2Rb
mAb (A41) were tested on TS1b cell proliferation induced by p1–30 (60
mM), IL-2 (1 nM), or IL-9 (10 nM). (D) Effects of two neutralizing anti–
mouse IL-2Rg mAbs (3E12 and 4G3 mAbs) on the IL-2– and p1–30-
induced proliferation of TS1b cells. Abs isolated from mouse ascitic fluids
were diluted and added to the cell culture. (E) Synergy between p1–30
and IL-4. Proliferative responses of TS1 (expressing mouse IL-2Rg),
TS1b (expressing human IL-2Rb and mouse IL-2Rg), and 8.2 cells (ex-
pressing mouse IL-2Rb and mouse IL-2Rg) were induced at various
concentrations of IL-4 (up to 100 U/ml) in the presence or absence of 60
mM of p1–30. Values obtained for p1–30 responses (Bkg) were subtracted
from the IL-4 plus p1–30 response. 
Table I. Sequence and Structure–Function Analysis of p1–30
Peptides Activity* Helix‡ State§ Kd
i
% mM
p1–10 ,5 0 M/D 50
APTSSSTKKT
p5–15 ,5 2 M/D 113
SSTKKTQLQLQ
p10–20 NT 0 M –
TQLQLEHLLLD
p1–22 ,5 5 M/D 65
APTSSSTKKTQLQLEHLLLDLQ
p10–30 50 35 M/D 0.2
TQLQLEHLLLDLQMILNGINN D/T 88
p1–30 100 50 M/T 5
APTSSSTKKTQLQLEHLLLD
LQMILNGINN T/O 60
p1–30Cys 100 50 M/T 5
APTSSSTKKTQLQLEHLLLD
LQMILNGINNC T/O 60
p1–30Cys-FLC NT 55 M/T 2
T/O 55
Amino acid sequence (top) of IL-2 and p1–30. Location of a helices (A–D)
is indicated by a box, and the critical region for binding to IL-2Rb is
shaded.
NT, not tested (p10–20 induced strong cellular aggregation).
*Percentage of the activity obtained with p1–30 in the presence of 1 nM
of IL-2.
‡Percentage of helix determined by CD.
§M, monomer; D, dimer; T, tetramer; O, octamer.
iAffinity of the oligomer formation.533 Eckenberg et al.
size exclusion chromatography. Most of the material mi-
grated as a single peak and eluted just before the 12.4-kD
marker, indicating that the major form of the peptide (3 kD)
could be a tetramer (Fig. 2 B). The chromatography pat-
tern also showed two small “shoulders” on both sides of the
main peak that could correspond to monomers (3 kD) and
octamers (26 kD).
The activity of peptide fragments (p1–22 and p10–30)
was studied on TS1b cells in the presence of IL-2 (Fig. 2 C).
Synergy was observed with peptides p10–30 and p1–30
only, which are the ones folded in an a-helical structure
(Fig. 2 A). Since p1–22 was not active, this strongly sug-
gested a role for the helical structure in the induction of the
biological effects observed.
Previous work reported that Asp20 is an essential residue
for both IL-2 activity and IL-2/IL-2Rb interaction (17,
21). Peptide p1–31 (p1–30 with an additional COOH-ter-
minal tyrosine) was mutated at position 20 (Asp®Lys) and
was analyzed as above (peptides p1–31 and p1–30 had a
similar activity at the proliferation level). The results
showed that the Asp20 substitution had no impact on p1–31
activity (Fig. 2 D), whereas the biological activity of IL-2
(Asp20®Lys20) mutant was clearly reduced (Fig. 2 E).
The structure–function relationship was further analyzed
by studying other peptides covering different portions of
the p1–30 sequence. Table I summarizes the most salient
data concerning peptide activity, helicity, and quaternary
structure. The quaternary structure of the peptides was
evaluated by sedimentation–diffusion experiments. At 10 mM,
p1–30 behaved essentially as a tetramer, whereas at 150 mM,
p1–30 showed significant amounts of octamer in equilib-
rium with the tetramer (see also Fig. 3 A). At 10 and 150 mM,
the molecular masses obtained for the lightest species ranged
from 10,340 to 16,480 daltons, providing an estimated
number of 4.0 6 0.9 peptides per oligomer. These results
are in close agreement with those obtained by chromatog-
raphy and with preliminary crystallization trials (crystals of
the peptide, which diffract at low resolution, were obtained
reproducibly), which confirm that the p1–30 tetramer has a
compact globular conformation. As described in Table I,
p1–10, p5–15, and p1–22 are dimers at 150 mM with Kd
values of 50, 113, and 60 mM, respectively. The p10–30
peptide is a tetramer at 150 mM by association of two dimers
with a Kd value of 88 mM. Altogether, the results shown in
Table I suggest that in p1–30, residues 10–30 may be re-
sponsible for the association of tetramers, and residues 1–10
may be responsible for the dimerization of tetramers to
form octameric species.
Binding of p1–30Cys-FLC to IL-2Rb 31–230. To study
directly the interaction of p1–30 with IL-2Rb, a truncated
IL-2Rb representing most of the extracellular part (residues
31–230) of the molecule was first produced and studied by
analytical ultracentrifugation. At 1 mM of protein, experi-
ments of sedimentation–diffusion at equilibrium showed an
association of two monomers with a Kd value of 3 3 1026 M.
Figure 3. Sedimentation–diffusion equilibrium of p1–30 and soluble
IL-2Rb. Profiles of absorbance versus radius from the center of rotation
were obtained by sedimentation–diffusion equilibrium at 25 krpm in
20 mM sodium phosphate, pH 7.2, at 208C. Residual errors as a function
of radial distance from the center of rotation show the fitting quality of
the data to the selected models. (A) p1–30 initial concentration was 150 mM.
Absorbance was recorded at 242 nm. A better fit was obtained with a tet-
ramer–octamer model of equilibrium (bottom) than with a tetramer
model (top). (B) IL-2Rb 31–230 initial concentration was 14 mM. Ab-
sorbance was recorded at 295 nm. An equilibrium monomer–dimer
model (bottom) seemed slightly better than a dimer model (top). (C) p1–
30Cys-FLC and IL-2Rb 31–230 initial concentrations were 150 and 14 mM,
respectively. Absorbance of p1–30Cys-FLC (at 490 nm) in the presence
or absence of IL-2Rb 31–230 is shown (top). Profile at 295 nm (aromatic
residue absorbance of IL-2Rb 31–230) of the peptide–protein mixture is
also shown (bottom).
Figure 2. Structure–function analysis of p1–30. (A) The CD spectra
from 180 to 260 nm are shown for p1–10, p5–15, p10–20, p1–22, p10–30,
and p1–30 at 150 mM. The p1–30 concentration dependence (3–150 mM)
of the CD signal at 192 nm is shown in the insert. (B) Size exclusion
chromatography. Peptide p1–30 was eluted as a single main peak of mo-
lecular mass 13 kD (according to column calibration). Arrows indicate
molecular weight (mw) markers, void volume (V0) and total volume (Vc).
Monomeric, tetrameric, and octameric forms are shown. (C) TS1b cell
proliferation was tested at various concentrations of IL-2 (from 5 3 1023
to 10 nM) with 60 mM of either p1–30, p1–22, or p10–30. The response
to IL-2 or peptide alone was subtracted from that obtained with both IL-2
and peptide. (D) Role of Asp20 in p1–31 activity. TS1b cells were stimu-
lated with various concentrations of IL-2 (from 5 3 1023 to 10 nM) in
the presence of 60 mM of peptide p1–31 or p1–31(Lys20). Results are
presented as in C. (E) The biological activity of mutant IL-2(Lys20) is
shown for comparison.534 IL-2 Partial Mimetic, Inducing LAK Cells
At 14 mM, the molecular mass obtained was very close to
the dimer mass (Fig. 3 B). The presence of p1–30 (150 mM)
along with IL-2Rb 31–230 (1 mM) did not influence IL-
2Rb 31–230 dimerization in solution (data not shown).
To verify that p1–30 binds to IL-2Rb 31–230 dimers,
we labeled the peptide with an FLC group on a COOH-
terminal cysteine (p1–30Cys-FLC) and analyzed its absor-
bance profile at 490 nm. p1–30Cys and p1–30Cys-FLC
showed a helical conformation depending on their concen-
trations and formed octamers and tetramers with Kd values
close to those of genuine p1–30 (Table I, and Fig. 3 A).
The absorbance profiles of p1–30Cys-FLC (150 mM) at
490 nm and of IL-2Rb 31–230 (14 mM) at 295 nm mixed
in the same cell are displayed in Fig. 3 C (top and bottom,
respectively). The data show that in the presence of IL-2Rb
31–230, p1–30Cys-FLC had a greater molecular weight.
The number of species at equilibrium in solution did not
allow the accurate calculation of the Kd value, but it was
found to be significantly higher than the peptide concen-
tration used in these experiments (150 mM). As expected,
the molecular weight of IL-2Rb 31–230 was not greatly
influenced by the presence of p1–30Cys-FLC.
Activation of Shc and p56lck by Peptide p1–30. Early events
of activation by p1–30 were investigated on Kit 225 cells.
Like TS1b cells, Kit 225 cells proliferated in response to
p1–30 (maximal proliferation was obtained at 60 mM of
p1–30; data not shown). We first analyzed the protein
phosphorylation pattern induced by IL-2, p1–30, or a
combination of both molecules by Western blot (Fig. 4 A).
Unlike in unstimulated cells, the phosphorylation of four
major proteins (p47, p52, p60, and p66) was clearly upreg-
ulated with p1–30 stimulation. The same proteins were
also hyperphosphorylated after IL-2 stimulation.
These results led us to investigate the activation state of
molecules known to participate in the IL-2–induced signal
transduction cascade. Stimulation with IL-2 is known to
involve the p21ras pathway via phosphorylation of the
adapter protein, Shc. Therefore, Kit 225 cells were stimu-
lated for 1, 2, 5, 10, and 15 min with p1–30 (Fig. 4 B).
Blotting of the membrane with the antiphosphotyrosine
mAb (top) showed an increase in the phosphorylation of
two bands (p47 and p52) that reached a maximum after 10
min of stimulation. The two phosphorylated proteins cor-
responded to the two Shc isoforms (p47 and p52) and were
loaded in equal quantity, as demonstrated by anti-Shc blot-
ting (bottom). As control, IL-2 stimulation (5 min) also in-
duced Shc phosphorylation.
Another important PTK implicated early during IL-2
signaling is p56lck. This protein is constitutively associated
with IL-2Rb and is presumed to phosphorylate Shc. We
examined the effect of p1–30 on the tyrosine kinase activ-
ity of p56lck. After similar stimulation of Kit 225 cells and
immunoprecipitation of p56lck, the immunoprecipitates were
tested for their ability to phosphorylate the exogenous sub-
strate, enolase (Fig. 4 C). Treatment with p1–30 resulted in
an increased enolase phosphorylation, indicating that p1–30
activates p56lck kinase activity. As control, IL-2 also induced
the kinase activity of p56lck. Fig. 4 C (bottom) also shows
that an equal quantity of p56lck was immunoprecipitated
and used in the in vitro kinase assay.
Implication of the Jak Proteins in p1–30 Signaling. IL-2 is
known to induce the tyrosine phosphorylation of Jak1 and
Jak3. Therefore, we investigated whether Jak proteins were
also phosphorylated in response to p1–30 (Fig. 5, A–F). Af-
ter stimulation, protein lysates of Kit 225 cells were immu-
noprecipitated with mAbs specific for different Jaks followed
by antiphosphotyrosine (4G10) immunoblotting (top panels)
or by anti-Jak immunoblotting (bottom panels). Interest-
ingly, as shown in Fig. 5, A and B, Jak1 and Jak3 were not
phosphorylated after p1–30 stimulation, whereas IL-2, as ex-
pected, induced the phosphorylation of these two proteins.
However, similar to IL-2, the peptide was unable to activate
Jak2 (Fig. 5 C). Finally, we examined the activation status of
Tyk2 (Fig. 5 D). Antiphosphotyrosine blotting showed acti-
vation of Tyk2 after p1–30 stimulation. Unexpectedly, IL-2
also induced Tyk2 phosphorylation in the Kit 225 cell line.
Under the same experimental conditions, IFN-a–induced
phosphorylation of Tyk2 was only twofold greater. Hence,
the kinetics of Tyk2 activation was studied (Fig. 5, E and F).
Maximal Tyk2 phosphorylation was reached after 15 min of
p1–30 stimulation and after 5 min of IL-2 stimulation.
In the IL-2 system, STAT5 is activated in a manner
dependent on Jak1 and Jak3. We studied the capacity of
p1–30 to induce the STAT pathway. Kit 225 cells were
stimulated, and nuclear extracts were subjected to electro-
Figure 4. Signal transduction induced by p1–30. (A) General pattern of
protein tyrosine phosphorylation. Kit 225 cells were stimulated for 10
min with IL-2 (10 nM), p1–30 (60 mM), or both. Cells were lysed, and
the pattern of protein tyrosine phosphorylation was visualized by SDS-
PAGE and immunoblotted with mAb 4G10, specific for phosphotyrosine
(P-TYR). Arrowheads indicate the phosphorylated proteins upregulated
by p1–30. (B) Phosphorylation of Shc. Kit 225 cells were stimulated for
1, 2, 5, 10, and 15 min. After lysis, phosphotyrosine-containing proteins
were detected with 4G10 mAb (top). The identity and equal loading of
the two Shc isoforms were confirmed by probing with the mAb to hu-
man Shc (bottom). (C) Induction of p56lck kinase activity. Kit 225 cells
were stimulated for 15 min with 10 nM of IL-2, 60 mM of p1–30, or a
combination of both. p56lck was immunoprecipitated and tested for its
ability to phosphorylate the exogenous enolase substrate (top). The bot-
tom panel shows that equal amounts of immunoprecipitated p56lck were
used in the kinase assay.535 Eckenberg et al.
phoretic mobility shift assay (EMSA) using an Fc-g gene–
derived IFN-g activation sequence (GAS) probe. Strikingly,
no bandshift was visualized after p1–30 stimulation, unlike
IL-2, which did induce complex formation. mAb to STAT5
but not to STAT3 “supershifted” the complexes formed af-
ter IL-2 stimulation. The absence of STAT activation by
p1–30 was confirmed using an additional probe (b-casein;
data not shown).
Figure 5. Implications of the Jak proteins in p1–30 signaling. (A–D)
Analysis of Jak protein activation. Cells were stimulated for 10 min as in-
dicated and immunoprecipitated with anti-Jak1 (A), Jak3 (B), Jak2 (C),
and Tyk2 (D) mAbs. Antiphosphotyrosine blotting (P-TYR, top) and
anti-Jak blotting (bottom) are shown. For C, the immunoblot displays
two bands because the commercial anti-Jak2 serum cross-reacts with Jak3.
However, the two kinases could be distinguished by their molecular
weights. For D, cells were stimulated with IFN-a (0.3 nM) as a positive
control for Tyk2 activation. (E and F) Analysis of Tyk2. Kit 225 cells
were stimulated for 2, 5, 10, 15, and 30 min with p1–30 (60 mM) or IL-2
(10 nM). After lysis and anti-Tyk2 immunoprecipitation, phosphoty-
rosine-containing Tyk2 was detected (top). The total amount of immu-
noprecipitated Tyk2 corresponding to each stimulation was verified (bot-
tom). (G) Activation of STAT proteins by IL-2 but not by p1–30. EMSA
was carried out on nuclear extracts of Kit 225 stimulated for 10 min with
IL-2 (10 nM), p1–30 (60 mM), or both. Nuclear extracts were incubated
with the GAS probe. Supershifted complexes were analyzed with anti-
bodies directed against STAT5, STAT3, or a nonrelevant serum (NRS)
after IL-2 stimulation.
p1–30 Activity on Human PBMCs. Since IL-2Rb is ex-
pressed on a proportion of low CD8-expressing (CD8low)
lymphocytes and more extensively on NK cells (27), we
investigated the effect of p1–30 on PBMCs. Human PBMCs
were first tested for p1–30-induced proliferation after 3 or
6 d of stimulation. Incorporation of thymidine was depen-
dent on the concentration of p1–30 and reached a maxi-
mum by day 3, which was maintained until day 6. In com-
parison, the IL-2 response was more efficient by day 3 but
declined by day 6 (Fig. 6 A). To further evaluate the activ-
ity of p1–30, we tested its ability to generate LAK cells, a
property attributed to IL-2 (4). PBMCs were stimulated
with IL-2 or p1–30 for 3 or 6 d, and the lysis of K562 and
Daudi target cells was evaluated (Fig. 6 B). p1–30 was able
to induce LAK cells in a concentration-dependent manner.
However, the response was weaker than that of IL-2 on
day 3, but values were comparable on day 6.
Induction of LAK cells was also studied with the peptide
p1–31(Lys20). Fig. 6 C shows a comparison of p1–30 and
p1–31(Lys20) activities at day 6 against K562 and Daudi
cells. The two peptides displayed a similar efficiency at 30 mM
when LAK cells were tested on K562 targets.
The influence of p1–30 on PBMC subset (B, T CD4, T
CD8, and NK cells) activation was also studied. Expression
of the early activation marker CD69 was followed after stim-
ulation with p1–30 or IL-2 by flow cytometry (Fig. 7 A). As
testified by the increased CD69 expression, p1–30 appeared
to specifically activate the CD8low and the NK cell subsets as
well as, to a lesser extent, the high CD8-expressing lympho-
cytes (CD8high). As positive control, IL-2 also induced CD69
expression on these populations. Marginal effects were ob-
served on the other subpopulations tested. p1–30 was also
shown to induce IFN-g production in PBMCs. Interest-
ingly, under some experimental conditions (2 d of culture),
p1–30 synergizes with IL-2 in this phenomenon (Fig. 7 B).
Discussion
Reconstitution of a neocytokine from the first 30 aa of
IL-2 is very novel in the field of peptide agonists. Recently
characterized peptides, with agonist activities related to cyto-
kines of the hemopoietin family, have consisted up to this point
of small mimetics of erythropoietin (EPO [28]) or throm-
bopoietin (29) selected by random phage display peptide li-
braries and a small nonpeptidyl mimic of G-CSF (30). These
compounds act as full agonists in various biological assays,
and their signaling pathways appear to be identical to those
induced by the natural ligand, yet their amino acid se-
quences are not found in the primary sequence of the natu-
ral protein. The crystal structure of the 20-aa mimetic pep-
tide of EPO and of the extracellular domain of the EPO
receptor (EPOR) reveals a dimerization of the peptide
that is bound to the homodimeric EPOR. In this study,
it was shown that the peptide p1–30 contains a part of
the native aa sequence of IL-2, forms a tetrameric structure
that mimics a cytokine with a configuration of four a
helices, and acts on cells expressing human IL-2Rb. The
peptide p1–30 also acts in synergy with IL-2 and IL-4. We536 IL-2 Partial Mimetic, Inducing LAK Cells
activity was observed, most of the molecules were in a
compact tetrameric form. The amino acid sequence of p1–30
shows 7 leucine residues (positions 12, 14, 17, 18, 19, 21,
and 25) and 2 isoleucine residues (positions 24 and 28)
among the 18 COOH-terminal residues. The periodicity
of these amino acids suggests that most of these side chains
form a hydrophobic face on the helix containing residues
10–30. The molecular weight of p1–30 suggests that four
of these faces could constitute a hydrophobic core, which
stabilizes the homotetramer. Consequently, four basic p1–30
peptides could form a molecule resembling a cytokine of
the hemopoietin family, composed of a compact core bun-
dle of four a helices.
The peptide p1–30 was initially designed for binding to
human IL-2Rb (21). Studies of its biological activities re-
vealed that p1–30 bound human IL-2Rb specifically and that
this binding was necessary to induce proliferation. The role of
the IL-2Ra and g subunits in direct binding to p1–30 was
eliminated, since the effects of p1–30 existed in the absence
of IL-2Ra expression (TS1b cells) and was not significantly
affected by neutralizing mAbs to IL-2Rg. Therefore, it ap-
pears that, unlike IL-2, p1–30 interacts with IL-2Rb only.
Figure 6. p1–30 activity on PBMCs. (A) Proliferation of PBMCs. PBMCs from
healthy human donors were stimulated with IL-2 (0.5 nM) or p1–30 (3, 30, 60, or
100 mM) for 3 or 6 d followed by measurement of thymidine incorporation. The
graph shows the negative control (white bars), IL-2–induced proliferation (black
bars), and the dose-dependent p1–30-induced proliferation (gray bars). (B) Induction
of LAK cells. PBMCs stimulated with IL-2 (0.5 nM) or p1–30 (3, 10, 30, 60, or 100
mM) for 3 or 6 d were tested for their ability to lyse K562 or Daudi target cells. Per-
cent lysis at different effector/target ratios is shown. (C) LAK cell induction by p1–
31(Lys20). The lysis of K562 or Daudi target cells by PBMCs stimulated with p1–30
or p1–31(Lys20) (30 mM) for 6 d was measured. Results obtained at different effec-
tor/target ratios are presented. Data of representative experiments are shown.
also demonstrate that p1–30 induces the phosphorylation of
Shc, an essential adapter in the initiation of the Ras/mito-
gen-activated protein kinase (MAPK) pathway, and the ac-
tivation of the PTK p56lck. Unlike IL-2, however, Jak1,
Jak3, and the STAT pathway were not activated after p1–30
treatment. Surprisingly, Tyk2 is phosphorylated upon both
p1–30 and IL-2 stimulation of Kit 225 cells. Finally, p1–30
is able to specifically activate CD8 T lymphocytes and NK
cells, and induces LAK cell–mediated cytotoxicity.
Studies of secondary and quaternary structures of p1–30
were undertaken. CD studies performed with p1–30 indi-
cated that a high proportion of the residues was in an a-heli-
cal configuration for concentrations ranging from 3 to
150  mM. The link between the secondary structure and the
biological effect was revealed by testing peptide fragments
p1–22 and p10–30. Peptide p10–30 was biologically active
and folded into an a-helical configuration, whereas peptide
p1–22, which did not form a helices, failed to exert any bi-
ological effect. The helicity of p1–30 depends on the con-
centration, suggesting that oligomerization of the peptide
stabilizes its folding. Quaternary structure studies of p1–30
indicated that, in a concentration range where its biological537 Eckenberg et al.
Since the biological effects of most cytokines are mediated
after hetero- or homodimerization of their receptor chains,
we hypothesized that the mode of action of tetrameric p1–30
was through an induction of IL-2Rb dimerization or bind-
ing to preformed dimers. These interactions are possible, since
tetrameric p1–30 has four potential binding sites for IL-2Rb.
Nevertheless, we cannot exclude that other membrane
molecules can also participate in the p1–30 receptor.
To further analyze this hypothesis, we produced a solu-
ble form of IL-2Rb and tested its ability to dimerize and
bind p1–30. Analytical ultracentrifugation showed that IL-
2Rb (31–230) alone was dimeric in solution at concentra-
tions ,1 mM. Using the FLC-labeled peptide p1–30Cys-
FLC, we studied its association with IL-2Rb (31–230) at
490 nm. The ultracentrifugation profile clearly showed the
association of p1–30Cys-FLC to dimeric IL-2Rb (31–230).
In view of these results, we propose that IL-2Rb dimers
(IL-2Rb)2 are formed before the binding of the p1–30
tetramer (p1–30)4, although induction of dimerization by
p1–30 cannot be excluded. The equilibrium constant for
IL-2Rb dimerization and (p1–30)4/(IL-2Rb)2 binding could
be significantly lower at the membrane level due to the bi-
dimensional diffusion of preoriented receptors. Under these
conditions, p1–30 could induce signals by changing the
conformation of (IL-2Rb)2 complexes. Several reports con-
cerning chimeric receptors constructed from the intracellu-
lar region of IL-2Rb and the extracellular region of other
homodimeric receptors indicate that IL-2Rb dimers can
transduce signals. A chimeric receptor EPOR/IL-2Rb
induces cell proliferation (31) and intracytoplasmic pro-
tein phosphorylation (32). Similarly, the chimeric receptor
G-CSFR/IL-2Rb induces the expression of reporter gene
constructs (33), and a chimeric receptor c-kit/IL-2Rb in-
duces cell proliferation (34).
Characterization of the specific signals induced by p1–30
revealed that the pattern of phosphorylation induced by
p1–30 was similar to that induced by IL-2. However, more
detailed investigations revealed clear differences. As in stimu-
lation with IL-2, Shc and p56lck were activated, but on the
contrary and consistent with the hypothesis that p1–30
does not recruit IL-2Rg, Jak1 and Jak3 were not phosphor-
ylated and the STAT pathway was not involved. In the
IL-2/IL-2R model, Shc and p56lck are dependent on the A
and S domains of IL-2Rb. The STAT pathway, however,
is dependent on the respective association of Jak1 and Jak3
with box1 domains of IL-2Rb and IL-2Rg. Therefore,
p1–30 signals appear to be dependent only on IL-2Rb, and
this supports the proposed (p1–30)4/(IL-2Rb)2 model de-
scribed above. Surprisingly, it was shown that p1–30, as well
as IL-2, induced Tyk2 phosphorylation. Signals were weaker
than the classical IFN-a–induced phosphorylation but were
confirmed by studying IL-2– and p1–30–stimulated PBMCs
(data not shown). Previous work has reported on the ab-
sence of IL-2–induced Tyk2 phosphorylation, but the data
were obtained under different experimental conditions (35).
Even if the implications of Tyk2 are of secondary impor-
tance in IL-2 signaling, this PTK could play an essential
role in p1–30 signal transduction, because no other Jaks
were found to be activated.
The relationship between p1–30 and IL-2, both of which
bind to the IL-2Rb protein and are able to act in synergy,
deserves further discussion. In the presence of IL-2, it has
been shown that the three receptor subunits interact to
form the high affinity receptor (36). The induction of the
trimeric receptor (a, b, g) may lead to the dissociation of
IL-2Rb dimers that could exist at the cell surface. When
p1–30 and IL-2 were present simultaneously, a synergistic
effect was observed. This may indicate that at the cell sur-
face there is an excess of IL-2Rb and a limited number of
IL-2Rg molecules, allowing a distribution of IL-2Rb ei-
ther in the p1–30R (IL-2Rb)2 or in the IL-2R. On TS1b
cells stimulated with p1–30 and IL-2, one may suggest that
some of the IL-2Rb molecules are included in the inter-
mediate affinity IL-2/IL-2Rbg complex (Kd 5 1029 M),
whereas free (IL-2Rb)2 complexes, which bind IL-2 very
weakly (Kd 5 1027 M), remain accessible for p1–30 bind-
ing. Simultaneous utilization of IL-2Rbg and p1–30R may
produce a coupled signal and explain the synergistic effects.
The signaling events leading to the synergy are not yet un-
derstood.
Figure 7. Activation of NK and CD8 T cells by p1–30 and induction
of IFN-g. (A) PBMCs were stimulated with IL-2 (0.5 nM) or p1–30 (10,
30, or 100 mM) for 1, 2, or 3 d. Subpopulations labeled with anti-CD4
(Th lymphocytes), CD8 (CTLs), CD20 (B lymphocytes), or CD56 (NK
cells) were assayed for CD69 expression. Graphs represent the percentage
of CD691 cells for each population with respect to stimulant (IL-2 or p1–
30) and time (day) of stimulation. Data of a representative experiment are
shown. (B) IFN-g production was measured on supernatants from PBMCs
stimulated with IL-2 (0.5 nM) or p1–30 (30 mM) at day 6. In a second
panel, synergy between IL-2 (0.5 nM) and p1–30 (30 mM) is shown after
2 d of stimulation.538 IL-2 Partial Mimetic, Inducing LAK Cells
The bioactivity of p1–30, particularly its ability to induce
LAK cells and IFN-g production, strongly suggests that it
may have therapeutic potential against tumor cells. As IL-2,
p1–30 induces a potent LAK cell response, as measured on
Daudi and K562 targets. Among immune cells, NK cells
and some CD8 T cells express large amounts of IL-2Rb
(27). Therefore, they were thought to constitute the major
targets of p1–30. Concordant with this hypothesis, analysis
of the p1–30 effects on human PBMCs clearly demonstrated
the peptide’s capacity to upregulate the expression of CD69,
especially on NK cells and CD8low lymphocytes. To further
confirm our results, we have verified that p1–30 acts on
purified NK cells either alone or in synergy with IL-2 (data
not shown). Moreover, we demonstrated the progression of
NK cells towards S and G2/M phases of the cell cycle after
p1–30 stimulation alone and in synergy with IL-2 (data not
shown). We have shown that p1–30 induces IFN-g pro-
duction, which also exhibits a strong activity against tumor
cells (37). This cytokine is able to upregulate surface ex-
pression of MHC antigens (both class I on tumor cells and
class II on antigen-presenting cells), and this results in the
potentiation of antitumor immunity. In addition, IFN-g is
capable of stimulating cytokine receptors, proteasomes, and
tumor-associated antigen expression. More interestingly,
IFN-g has a direct inhibitory effect on tumor cell prolifera-
tion and may play a role in the triggering of programmed
cell death (38).
IL-2 is also known to induce various side effects in vivo.
An important aspect of toxicity mediated by IL-2 is vascu-
lar leak syndrome (VLS). It involves damage of vascular en-
dothelial cells leading to vascular leak, edema, and organ
failure. Recent work (39) provides evidence that a struc-
tural motif in IL-2 and other VLS-inducing proteins may
be responsible for binding to endothelial cells and initiating
VLS. This motif is located in the a helix A of IL-2, cen-
tered on Asp20. Short peptides containing aa 15–23 of IL-2
and exhibiting this motif induce VLS, whereas mutated
peptides do not. We generated a mutated peptide, p1–
31(Asp20®Lys), abrogating this motif and showed that its
inductive capacity on proliferation was maintained, con-
trary to IL-2 mutated at the same position. This suggested
that the interaction of p1–30 with IL-2Rb is somewhat differ-
ent from the IL-2/IL-2Rb interactions. p1–31(Asp20®Lys)
also maintained its capacity to generate LAK cells (Fig. 6 C)
and to induce IFN-g production (data not shown). We dem-
onstrate here the possibility of generating IL-2 mimetics,
which maintain stimulatory activity on lymphocytes but
lack the potential to damage vascular endothelial cells.
In this work, we have shown that a single a helix of IL-2
keeps its properties of binding to one of the IL-2R chains,
(IL-2Rb)2. The a helix (p1–30) is a neocytokine directed
towards cells expressing IL-2Rb, including those (NK and
CD8low lymphocytes) involved in cytotoxic responses. The
p1–30/IL-2Rb and IL-2/IL-2Rb interactions are differ-
ent, and this may allow for the generation of different sets
of signals having different biological consequences. In gen-
eral terms, we have shown that a cytokine fragment can act
as a selective agonist of a critical cytokine receptor chain.
The present observations may be extended to other cyto-
kine–cytokine receptor systems, and this may have funda-
mental and practical implications.
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